Neurogene patient had life-threatening side effect in Rett syndrome studynews2024-11-18T19:55:48+00:00November 18th, 2024|Endpoints News|
Regenxbio shares first data showing Duchenne gene therapy improves muscle functionnews2024-11-18T16:24:37+00:00November 18th, 2024|Endpoints News|
A rare neurological disease is Sage’s last, best hope after failures in depressionnews2024-11-18T16:22:00+00:00November 18th, 2024|Endpoints News|
As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteersnews2024-11-18T16:03:59+00:00November 18th, 2024|Endpoints News|
Cybin reports high remission rates for psilocin drug in Phase 2 depression testnews2024-11-18T12:00:42+00:00November 18th, 2024|Endpoints News|
Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis assetnews2024-11-18T09:09:43+00:00November 18th, 2024|Endpoints News|
Scottish biotech Trogenix debuts with viral immunotherapy platform for cancernews2024-11-18T07:00:06+00:00November 18th, 2024|Endpoints News|
Eisai terminates Phase 3 trial of Dravet drug lorcaserinnews2024-11-17T10:27:08+00:00November 17th, 2024|Endpoints News|
Eyenovia’s stock falls after it halts late-stage myopia trialnews2024-11-15T16:01:01+00:00November 15th, 2024|Endpoints News|
Boston Pharmaceuticals’ Phase 2 MASH trial hits efficacy endpointsnews2024-11-15T16:00:21+00:00November 15th, 2024|Endpoints News|
